Tweet SAN DIEGO, CA, Primmune Therapeutics today announced that it has raised $7 million in seed financing.

To export Primmune Therapeutics funding data to PDF and Excel, clickClick here for more funding data on Primmune TherapeuticsTo export Primmune Therapeutics funding data to PDF and Excel, click here Primmune Therapeutics today announced that it has raised $7 million in seed financing to support the development of novel orally-administered, small molecule toll-like receptor 7 (TLR7) agonists for long-term systemic activation of innate immunity.

Most recently, Mr. McDermott was President, Chief Business Officer, and a member of the board of directors of Impact Biomedicines, Inc.

To this end, Mr. McDermott helped raise approximately $190 million via private equity, debt, and an initial public offering.

Before Primmune, Mr. Rangel was President & CEO and Co-founder of Evince Biosciences, a precursor to Primmune Therapeutics. | To read full story, visit https://startuparound.com/read/1583186406.9449139/Primmune-Therapeutics-Inks-$7M-Seed-Financing?ref=audio_experience